UEG Week: Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes

Contributed by: PR Newswire

Tags

UEG-Week

More Like This

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

PR Newswire associated0

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event

EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

PR Newswire associated0

Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

PR Newswire associated0

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

PR Newswire associated0

Morphic Medical Announces CE Mark for RESET® Endoscopic Device Therapy

PR Newswire associated0

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions